Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis

To date, no head-to-head trials have compared the efficacy of brigatinib and alectinib against anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p), ALK-inhibitor-naïve, advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. We conducted an indirect trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Koichi, Akimoto, Kaho, Sato, Hiroki, Manabe, Ryo, Kishino, Yasunari, Homma, Tetsuya, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Sagara, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226463/
https://www.ncbi.nlm.nih.gov/pubmed/32290309
http://dx.doi.org/10.3390/cancers12040942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226463/
https://www.ncbi.nlm.nih.gov/pubmed/32290309
http://dx.doi.org/10.3390/cancers12040942

Ejemplares similares